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ABSTRACT 
 
Effects of Estrogen and Phytoestrogens on the Development of Colonic Inflammation. 
(May 2012) 
 
Kari M’Lynn Galipp 
Departments of Nutrition and Food Science and Biology 
Texas A&M University 
 
Research Advisor: Dr. Clinton Allred 
Department of Nutrition and Food Science 
 
 
Colon cancer exhibits the third highest cancer mortality rate of the US. Patients with 
inflammatory bowel disease (IBD) display a much higher risk for development of the 
disease. Women experience protective effects against colon cancer due to naturally 
increased levels of estrogen compared to men. Preliminary studies were performed to 
determine methods of producing an IBD mouse model displaying suitable levels of 
inflammation for future studies regarding the effects of estrogen in a precancerous state. 
By inducing colon inflammation to create an IBD model, appropriate levels of estrogen 
supplementation will be obtained to enhance the results of future investigations. In phase 
one, male mice were exposed intrarectally to varying amounts of trinitrobenzene 
sulfonic acid (TNBS), and a relevant IBD state was achieved by the 3% TNBS dose, 
which was then used in phase two. For this phase, colitis was induced with TNBS in 
ovariectomized (OVX) female mice supplemented with varied levels of estrogen. TNBS 
induced inflammation and was not detrimental to mice at the 3% TNBS solution 
exposure level. OVX mice supplemented with estrogen achieved the colitis state without 
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additional health implications. Mice supplemented with .5 mg implants displayed 
estrogen blood levels half the value of those with 1 mg estrogen implants. Results 
obtained in this pilot study represent the first step toward determining how estrogen may 
decrease the risk of inflammation-associated development of colon cancer.  
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NOMENCLATURE 
 
EIA Enzyme Immunoassay  
ER Estrogen Receptor  
ERα Estrogen Receptor-α 
ERβ Estrogen Receptor-β 
IBD Inflammatory Bowel Disease 
OVX Ovariectomized 
TNBS Trinitrobenzene Sulfonic Acid  
WT Wild Type 
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CHAPTER I 
 
INTRODUCTION 
Colon cancer 
Colon cancer is the third most prevalent type of cancer diagnosis within the US 
population, and also is the third highest cause of cancer mortality. An estimate of 
141,210 people will be diagnosed with the disease and 49,380 deaths will be caused by 
colon cancer in 2011, according to predictions of the American Cancer Society (1).  
 
Colon cancer affects both men and women, especially in developed nations, and is 
considered a hormone-dependent cancer, largely influenced by estrogen. The influence 
of estrogen is evident due to the low number of women inflicted with the disease 
compared to men, as well as the protection exhibited by hormone supplementation. The 
risk factors associated with colon cancer range from age, gender, family history, 
previous infliction with colonic diseases, and exposure to procarcinogens in the 
environment and the diet. Current treatments consist of surgery, chemotherapy, and 
radiotherapy. The desire to shift toward chemopreventive actions focuses on the 
examination of dietary modifications and hormone supplementation for disease 
intervention and control (2). Diet is a factor that can easily be adjusted and offers a 
unique opportunity to target the colon through exposure to digested compounds (3).  
 
      ____________ 
      This thesis follows the style of The Journal of Nutrition. 
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The development of colon cancer is promoted by oxidative stress, inflammation, genetic 
damage, and changes to normal molecular processes (2). The progression can begin as a 
result of chronic inflammation, which is a characteristic of inflammatory bowel disease 
(IBD). Patients with IBD display an increased risk of developing colon cancer, and 
insight to this correlation can be gained through an animal model of the disease.  
 
Estrogen 
Estrogen exhibits a protective role against the development of colon cancer as the 
hormone substrate of estrogen receptor beta (ERβ), the predominant estrogen receptor of 
the digestive tract epithelium. As the disease state of colon cancer advances, the 
expression of ERβ declines, influencing many aspects of the progression pathway, such 
as the inhibition of cell cycle arrest and decrease of apoptosis (4).  The correlation of 
estrogen and colon cancer prevention is evident through the larger risk of colon cancer 
for men compared to women, along with the additional decreased risk for women who 
use hormone replacement therapy and oral contraceptives compared to those who do not 
receive supplementary hormones (5).   
 
Phytoestrogens 
Phytoestrogens are natural plant derivatives present in the diet that structurally resemble 
estrogen (Table 1) and have the ability to imitate its function by binding to estrogen 
receptors (4). Phytoestrogens exhibit a broad range of potential health benefits including 
antioxidant, anti-inflammatory, and free radical reduction (2).  
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There are three major classes of phytoestrogens, consisting of isoflavones, lignans, and 
coumestans. Isoflavones, especially genistein, have received the most attention for their 
potential biological activities and are found in soybeans, legumes, and peanuts (6). The 
absorption of phytoestrogens utilizes the intestinal microflora, and is an important 
process for the proper metabolism of these compounds and their eventual ability to affect 
the pathways leading to colon cancer (4).  
 
 
Table 1 – Common Phytoestrogen Structures: A comparison of phytoestrogens to the 
endogenous form of estrogen, estradiol (7).  
    
Estradiol 
 
Genistein  
 
    
Glycitein 
 
Quercetin 
 
    
Daidzein 
 
Resveratrol  
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Phytoestrogens possess many possible mechanisms that could account for their effects 
on colon cancer pathways. The most obvious method of phytoestrogen action is through 
its interaction with estrogen receptors, and its high binding affinity for ERβ to produce 
the effects of hormonal mechanisms. However, phytoestrogens also display ER-
independent effects on colon cancer pathways, including the regulation of gene 
expression that influences signaling cascades and reduces proliferation, inflammation, 
metastasis, and angiogenesis (2). The chemopreventive effects of phytoestrogens can 
infuence both the initiation and promotion of colon cancer tumors. The mechanisms 
include many different targets that can be studied through cell-culture models, the use of 
animal experiments, and clinical trials. 
 
To begin to study the roles of estrogen and phytoestrogens in inflammation-associated 
colon cancer, we aimed to develop an IBD mouse model for use in future investigations. 
The inflammatory agent trinitrobenzene sulfonic acid (TNBS) was selected for its 
potential to induce inflammation in the colon emulating that observed in ulcerative 
colitis. We sought to determine the levels of TNBS necessary to achieve the amount of 
inflammation relative to that detected in the colons of human IBD patients. Another 
parameter of the study tested the coordination of estrogen supplementation levels with 
TNBS exposure and the relationship between the two compounds within the animal 
model.  
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CHAPTER II 
MATERIALS AND METHODS 
 
The materials and methods utilized to conduct the study were carried out as a pilot study 
for future investigations. A sample group of mice was induced with colon inflammation 
using variable amounts of TNBS. Following the stimulation of colitis, the animals were 
sacrificed to collect data to determine the optimum level of TNBS exposure that resulted 
in the most accurate representation of IBD symptoms and the disease state, while 
causing fewer unwarranted ailments. The second phase observed the effects of estrogen 
supplementation and its suitable combination with the TNBS exposure. The findings will 
be used in future studies to induce inflammation in mouse models to observe additional 
parameters of estrogen influence on colon cancer.  
 
Mouse model   
Sexually mature C57BL/6 WT mice were utilized in both phases of the study. The first 
phase used male mice that received no estrogen supplementation. During the second 
phase of the trial, female mice were ovariectomized and implanted with supplemental 
pellets of estradiol (E2) two weeks prior to initial TNBS treatments. The females 
received sylastic implant pellets in doses of .5 mg E2 + 19.5 mg of cholesterol, or 1 mg 
E2 + 19 mg cholesterol. All mice were weighed prior to treatment.  
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TNBS 
TNBS induction of colitis is an important parameter of the study, with the purpose to 
mimic inflammation indicative of ulcerative colitis. TNBS was administered to the 
animals via intrarectal injection. The TNBS solutions were prepared according to the 
guidelines of Nature Protocols (8).  
 
The first phase of the study consisted of 5 experimental groups of 4 male mice apiece. 
Each group was assigned a specific concentration of TNBS, including a control group 
(0%), 1, 2, 3, and 4% TNBS solutions. The animals were presensitized to the TNBS 
solutions to promote increased colonic response one week prior to intrarectal treatment, 
as indicated in Figure 1. Dermal presensitization to TNBS is thought to increase 
subsequent immune response to the chemical (8). Animals were treated with TNBS 5 
days prior to sacrifice, and the optimum TNBS concentration found in this stage was 
utilized in Phase 2 of the study.  
 
Phase 2 utilized 16 female OVX mice divided into 4 trial groups. Two groups were 
supplemented with .5 mg E2, and two received 1 mg E2 pellets. Presensitization occurred 
one week prior to TNBS treatment, which was administered 5 days prior to sacrifice. 
One group of each supplementation level was treated with 3% TNBS solution 3 weeks 
after E2 implantation (Group A), while the remaining two groups were treated 7 weeks 
after E2 exposure (Group B).  
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Figure 1 – Study design. Both Phases of the study utilized sexually mature C57BL/6 WT mice. The first 
Phase used male mice to set the control levels of TNBS exposure. Phase 2 used the optimum TNBS levels 
found in Phase 1 on female mice to observe the interactions of estrogen supplementation and TNBS-
induced inflammation.  
 
 
 
Tissue collection 
Mice were weighed immediately before sacrifice, and any abnormalities in health were 
noted. The animals were humanely euthanized in order to collect appropriate tissues and 
data related to the effects of the chemical administered. The colons were collected and 
measured in length (cm) and weight (g). The inflammatory damage caused by TNBS 
exposure was assessed macroscopically. Trends in animal weight loss were investigated, 
as well as the ratio of colon length to colon weight as a measure of induced 
inflammation, which increases the ratio as length decreases and weight increases.  
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Enzyme immunoassay  
At the time of sacrifice, the blood of the phase 2 animals was also collected for plasma 
analysis of E2 levels. The Enzyme Immunoassay (EIA) was performed using the 
Estradiol EIA Kit (Cayman Chemicals) and following the outlined procedures.  
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CHAPTER III 
RESULTS 
Phase 1 
The male mice in the first phase of the study showed a general decrease in weight across 
each group from presensitization to treatment, then a general increase in weight, as 
evident from Figure 2. The 4% TNBS group showed a large weight decrease, however, 
indicating the toxicity of the higher levels of the inflammatory agent. This group also 
displayed visible signs of poor health, including lethargy and dehydration.   
 
 
 
 
 
Figure 2 –Weight of Phase 1 male mice measured at 1) presensitization, 2) treatment, and 3) sacrifice. 
The data shows a general decrease in weight across all treatment groups in the first period. The 4% TNBS 
group displayed the only weight decrease of all groups after treatment, with an average weight loss of 
almost 9g per animal. Poor health and extreme colon damage were visibly evident for this treatment group, 
indicating the toxicity of the 4% exposure level.     
25 
27 
29 
31 
33 
35 
37 
39 
41 
43 
1 2 3 
W
ei
gh
t (
g)
 
Control 
1% TNBS 
2% TNBS 
3% TNBS 
4% TNBS 
  10 
 
 
Figure 3 – Weight to length ratio of colons per Phase 1 treatment group. Colons of animals that received 
lower TNBS exposure displayed lower weight to length ratios. Groups displayed ratios of 0.0376, 0.0409, 
0.0472, 0.0481, and 0.0556, respectively.   
 
 
 
Following sacrifice, the colon of each animal was weighed and measured. In a weight to 
length ratio, the colons of animals that received lower TNBS doses displayed lower 
ratios, with a general upward trend, indicating higher levels of inflammation. The 4% 
TNBS group displayed a ratio of .0556, compared to the .0376 ratio of the control group. 
The general trend can be seen in Figure 3. Along with a high colon weight to length 
ratio, the 4% group displayed visible damage and inflammation to the colon upon 
removal, leading to fragile colons difficult to harvest and cleanse of excretory debris. 
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From the results of the first leg of the study, it was decided that the 3% TNBS exposure 
level provided a desirable IBD model without excess toxicity to the animal. The female 
mice of the second phase were treated with a 3% TNBS solution in order to monitor the 
estrogen variable and its relationship to the inflammation model.  
 
Phase 2 
In the short estrogen exposure group of female mice, the colon weight to length ratio 
exceeded those of both the male control group and standard 3% TNBS group. Figure 4 
shows the comparison of these ratios. Data could be slightly skewed, as 3 of the 4 high-
level estrogen mice were sacrificed 4 days early due to adverse response to the 
experimental treatment.  
 
 
 
 
 
Figure 4 – Weight to length ratio of colons in Phase 2 Group A short-term estrogen exposure. Females 
receiving 0.5mg E2 pellets displayed a ratio of 0.0600, and those with 1.0mg implants showed an average 
0.0558 ratio. These ratios are compared to the 0.0376 and 0.0481 ratios of the Phase 1 male control and 
3% TNBS groups, respectively.  
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Figure 5 – Weight to length ratio of colons in Phase 2 Group B long-term estrogen exposure. Females 
receiving 0.5mg E2 pellets displayed a ratio of 0.0630, and those with 1.0mg implants showed an average 
0.0578 ratio. These ratios are compared to the 0.0376 and 0.0481 ratios of the Phase 1 male control and 
3% TNBS groups, respectively.  
 
 
 
Mice that received a longer exposure period to estrogen followed a similar trend, evident 
in Figure 5. Again, several mice did not reach the end of the study, but data from both 
groups were available to compare.  
 
Estrogen levels  
Finally, the estrogen levels present in the blood of 1 mg estrogen implant mice were 
twice those of mice that received a .5 mg implant for both the short and long exposure 
groups. Figure 6 also shows that the long exposure group displayed levels of blood 
estrogen that were roughly half of the shorter exposure group, indicating that the levels 
decrease over time according to the amount of estrogen remaining in the pellet.  
0 
0.01 
0.02 
0.03 
0.04 
0.05 
0.06 
0.07 
W
ei
gh
t (
g)
 /L
en
gt
h 
(c
m
)  
Control 
Male 3% TNBS 
0.5mg E2 
1mg E2 
  13 
 
Figure 6 – Plasma levels of estrogen measured in Phase 2 female mice. The Enzyme Immunoassay (EIA) 
was performed using the Estradiol EIA Kit (Cayman Chemicals) and followed the outlined procedures. 
Estrogen levels present in the blood of 1mg estrogen implant mice were twice those of mice that received 
a 0.5mg implant for both Group A (short) and Group B (long) exposure groups. The long exposure group 
displayed levels of blood estrogen that were roughly one half of the shorter exposure group, indicating that 
the blood levels decrease over time according to the amount of estrogen remaining in the pellet.    
 
 
 
 
The blood levels of estrogen were investigated to determine the proper supplementation 
to imitate levels displayed by a human female throughout the hormonal cycle. These 
levels provide a good background for future studies and suggest that a plasma estrogen 
level near 1.50 nM at the time of TNBS exposure should be targeted.  
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CHAPTER IV 
SUMMARY AND CONCLUSIONS 
 
According to the results obtained, the administration of TNBS successfully induced 
inflammation and was not detrimental to mice at the 3% TNBS exposure level. Although 
there were several premature mortalities during the study, it is not thought to correlate 
with TNBS exposure, but another unknown error that may be ruled out in future studies 
with larger sample sizes. The mortalities observed were generally confined to single 
cages and could be the result of cage-specific disease. In the future, mice should be 
caged in smaller groups to lessen the impact of the proposed cage effect.  
 
Mice that were OVXed and supplemented with estrogen achieved the colitis state 
without additional health implications for other organ systems. This finding is especially 
important for future studies that will utilize the TNBS-induced inflammation model in 
place of previous problematic models. This model will be used to study the effects of 
phytoestrogens, particularly genistein, on the development and treatment of the inflamed 
colitis state.  
 
The blood estrogen levels achieved by supplementation reflect those of a cycling human 
female. Mice supplemented with 0.5 mg E2 implants displayed estrogen blood levels 
approximately half the value of those that received 1.0 mg E2 implants. The ratio 
observed indicates that levels of estrogen circulating in the bloodstream are predictable 
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and can be controlled according to the concentration of the supplement. The level is 
therefore dose-dependent and also decreases with time as the pellet is distributed and 
diminished. In future studies, it would be interesting to obtain blood data periodically in 
order to produce a curve denoting the blood levels over time. The resulting blood levels 
indicate that future studies with a long-term estrogen exposure should utilize a higher 
concentration of estrogen, while those with shorter exposure should make use of the 
smaller dose of estrogen. The plasma estrogen concentration of 1.50 nM demonstrated 
an effective combination with TNBS administration.  
 
Results obtained in this pilot study represent the first step toward determining how 
estrogen and phytoestrogens may decrease the risk of inflammation-associated 
development of colon cancer. The knowledge gained about the TNBS model will be 
utilized in future studies involving dietary phytoestrogens and their effects on 
inflammation in the colon. The subsequent study is currently planned and funded, and 
will begin once proper sample sizes are available. Future studies will also further 
investigate the development of colon cancer as a consequence of IBD once additional 
information has been obtained regarding the inflammation pathways phytoestrogens 
affect.  
 
The outcomes of this study and its future counterparts will provide a strong foundation 
for the advancement of colon cancer treatment and prevention in humans. Because the 
model closely resembles the IBD state of a human colon, future findings on the effects 
  16 
of estrogen and phytoestrogens will be applied to the battle against colon cancer and 
could lessen its devastating affects on high-risk populations. The increasing knowledge 
of pathways involved in colon cancer and precursor diseases may also be helpful in the 
study of other disease states and cancers and will have a large impact on the increased 
success of future medical efforts.  
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